{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"1","upperLimit":"60","value":"42"},{"groupId":"OG002","lowerLimit":"10","upperLimit":"60","value":"35"},{"groupId":"OG003","lowerLimit":"60","upperLimit":"60","value":"60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"description":"DOR will be calculated to determine durability. Non-responders will be excluded from the analysis of DOR. Kaplan Meier methodology will be used to estimate event-free curves.","dispersionType":"Full Range","groups":[{"description":"Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRituximab: Given IV","id":"OG000","title":"Treatment (Ixazomib Citrate, Rituximab) for CLL/SLL"},{"description":"Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRituximab: Given IV","id":"OG001","title":"Treatment (Ixazomib Citrate, Rituximab) for FL"},{"description":"Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRituximab: Given IV","id":"OG002","title":"Treatment (Ixazomib Citrate, Rituximab) for MZL"},{"description":"Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRituximab: Given IV","id":"OG003","title":"Treatment (Ixazomib Citrate, Rituximab) for MCL"},{"description":"Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRituximab: Given IV","id":"OG004","title":"Treatment (Ixazomib Citrate, Rituximab) for WM/LPL"}],"paramType":"MEAN","populationDescription":"No patients with CLL/SLL or WM/LPL met criteria to be included in DOR.","reportingStatus":"POSTED","timeFrame":"From the time by which the measurement criteria are met for CR or PR, whichever is recorded first, until death or the first date by which recurrent or progressive disease is objectively documented, assessed up to 5 years","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}